Close

iBio Launches New Sterile Fill-Finish Services

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...
- Advertisement -

iBio, Inc introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics.

Designed for clients with preclinical and clinical stage programs, the operation is housed in the Company’s 135,000 square foot CDMO facility located in Bryan, Texas.

“Providing Fill-Finish services is a natural extension of iBio’s FastPharmingTM biologics CDMO capabilities,” said Robert Kay, CEO. “Given our ability to quickly deliver GMP and research quantities of active pharmaceutical ingredient (API), the addition of the fillfinish operation completes our rapid, end-to-end service offering.”

The sterile liquid fill-finish operation will incorporate in-line labeling, allowing serialization of vials as they are filled. Initial capacity supports 100 – 2,500 vials runs, with plans to expand to 15,000. iBio will be presenting more details on its 5mL vial and 100mL bottle filling services at BIO 2019 in Philadelphia, PA, taking place June 3-6.

“We understand the needs of early stage companies, who often face moving targets for their timelines and support requirements,” commented Nicolas Taquet, Vice President, Biopharmaceutical Manufacturing. “It is often problematic trying to identify available capacity for high-quality, small volume filling. We’re now in position to fill that need for our clients.”

About iBio
iBio is a global leader in plant-based biopharmaceutical contract development and manufacturing services. With iBio’s FastPharmingTM protein expression and glycan
engineering technologies, consistently high-quality biologics can be produced rapidly in plants using automated hydroponic systems at iBio CDMO, LLC in Bryan, Texas. In addition to GMP contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with regulatory and facility design consulting as part of an end-to-end solution. For more information, visit www.ibioinc.com

About BIO International
BIO, taking place June 3-6, 2019 in Philadelphia, PA, features the latest trends, technology, companies, and breakthrough ideas in biotech and pharma. BIO is
expecting nearly 16,000 attendees with 1,800 exhibiting companies and delegations from 67 countries Visit iBIO at Booth #3059. For more information about BIO, visit
https://convention.bio.org/bio-exhibition/

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

CDSCO to Introduce Integrated Drug Regulatory Platform in 18 Months

The Central Drugs Standard Control Organisation (CDSCO) has announced...

Resilience and Eli Lilly Expand Strategic Partnership with $750 Million Ohio Manufacturing Investment

Resilience has announced an expansion of its strategic partnership...

WHO Introduces Global Regulatory Framework for Decarbonizing Pharmaceuticals

The World Health Organization (WHO) has officially launched the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »